相关实验视频
Updated: Jan 12, 2026

08:36
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
1.5K
亚努斯酶选择性如何影响阿布罗西提尼布在亚托皮炎的疗效和安全性:专家共识小组的专家共识小组
Angela Rosenberg1, Danny Zakria, Lauren DeBusk
1Department of Dermatology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Dermatology online journal
|October 31, 2025
概括
阿布罗西提尼布可以在中度至重度的亚托邦性皮肤炎中快速缓解. 它的安全性概况与其他Janus激酶1抑制剂相当,严重感染和心血管事件的风险较低.
科学领域:
- 皮肤病学 皮肤病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 亚托皮炎是一种慢性炎症性皮肤疾病,影响生活质量.
- 阿布罗西替尼可选择性地抑制Janus激酶1,向关键的炎症途径.
- 存在关于Janus激酶抑制剂的担忧,原因是对严重不良事件的盒子警告.
研究的目的:
- 为了评估abrocitinib对亚托邦性皮肤炎的安全性.
- 评估Janus激酶1选择性对abrocitinib的副作用概况的影响.
- 制定关于abrocitinib在治疗亚托皮性皮肤炎的使用的共识陈述.
主要方法:
- 通过文献搜索,发现了36项相关的英语研究.
- 一个由八名皮肤科医生组成的小组审查了文献.
- 为了达成共识陈述,使用了修改后的Delphi方法.
主要成果:
- 阿布罗西替尼在中度至重度的亚托邦性皮肤炎中显示出快速缓解.
- 该药物对Janus激酶1具有更大的选择性,并且比生物药物有效性更高.
- 它的安全性概况与其他Janus激酶1抑制剂相似,严重感染,心血管事件和血栓形成的风险较低.
结论:
- 阿布罗西替尼 (abrocitinib) 是一种有效的皮炎治疗方法,可快速缓解症状.
- 与较少选择性抑制剂相比,其对Janus kinase 1的选择性可能有助于有利的安全性.
- 专家的共识支持其使用,强调与安慰剂和类似的Janus激酶抑制剂相比,严重不良事件的风险较低.
相关概念视频
The JAK-STAT Signaling Pathway
11.9K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
11.9K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
1.7K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
1.7K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
476
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
476
Allergic Drug Reactions
1.3K
Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing...
1.3K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
475
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
475
Asthma-IV: Diagnostic and Management
3.1K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
3.1K

